Xandar Kardian, a Toronto, Canada-based company that develops contactless health monitoring solutions powered by digital ultra wide-band radar signal processing, closed a $10m Series A funding round.
The round was led by Phoenix Venture Partners, Portfolia Active Aging & Longevity Fund and Taronga Ventures, among other investors.
The company intends to use the funds to continue to expand operations and its development efforts.
Founded in 2017 as a US Delaware C-Corp with international operations spanning South Korea, Canada and the United States and led by CEO and founder Sam Yang, Xandar Kardian provides the XK300 Autonomous Health Monitoring Solution, a commercially available, contact-free, continuous VSM (vital sign monitoring) system that is FDA 510(k) cleared as a class II medical device. By introducing a contactless solution for continuous and autonomous vital sign monitoring, including resting heart rate and respiratory rate, Xandar Kardian enables patient monitoring and at-home care through accurate measurements that can be leveraged to predict health outcomes for better proactivity by providers.